was confirmed by detection of positive IgM antibody and/or viral genome in patient serum samples. Molecular and serological analyses were performed at the Virology Reference Laboratory of the Refik Saydam National Public Health Agency (Ankara, Turkey). The TaqMan-based one-step reverse-transcriptase PCR assay (RT-PCR) was used to detect CCHF viral RNA. 13 The presence of CCHFspecific serum IgM antibodies was determined by in-house ELISA method. The antigens used in the ELISA tests were obtained from the Centers for Disease Control and Prevention (CDC, Atlanta, GA, USA). Patient demographic, clinical, and laboratory data were recorded on individual forms. The control group (n = 43) was chosen from healthy solid organ donors who presented to the Organ Transplantation Center and who were living in the same regions as the CCHF patients. Ethics committee approval for genetic studies was obtained. All patients and control group members provided informed consent for participation in a genetic study.
HLA typing
HLA typing for A, B, Cw, DQB, and DRB loci was done using a medium-resolution PCR sequence-specific oligonucleotide (PCR-SSO) technique. For this purpose, LIFECODES HLA SSO typing kits were provided by Gen-Probe Transplant Diagnostics (Gen-Probe Transplant Diagnostics, Inc., Stamford, CT, USA). When the typing results indicated more than two possible alleles, high-resolution PCR kits with sequence-specific primers (PCR-SSP; Olerup SSP AB, Saltsjö baden, Sweden) were used to resolve ambiguities. The frequencies of HLA alleles, haplotypes, and genotypes were determined for all of the patients and control group.
Definition of severe cases
Previously reported disease severity criteria were used to define the severe cases.
14 Patients with at least one of the following were considered as severe cases: somnolence, melena, activated partial thromboplastin time (APTT) !60 s, and thrombocyte count 20 Â 10 9 /l. Fatal cases were also included in the severe group.
Statistical analysis
The frequencies of HLA alleles were compared between the patients and control group and between the non-severe and severe cases. Statistical analyses were performed using SPSS 15.0 statistical package (SPSS Inc., Chicago, IL, USA). Variables were compared by Chi-square test and Fisher's exact test with Yates' correction. The level of significance was set at a p-value of <0.05.
Results
The study was performed on 57 adult CCHF patients (31 male, 26 female) and 43 healthy controls (22 male, 21 female). There was no significant difference in the area of residence between the patients and controls (p = 0.283). In the patient group, HLA-A*02, HLA-B*35, HLA-Cw*04, HLA-DRB1*11, and HLA-DQB1*03 had the highest frequencies in their own HLA loci (Table 1) . When comparing the frequencies of HLA alleles between the patients and the control group, the frequency of HLA-A*02 was found to be significantly higher in the patients than in the healthy controls (p = 0.021). On the other hand, a significantly lower frequency of HLA-B*27 was observed in the patients than in the healthy controls (p = 0.01).
According to the categorization of the patients by severity criteria, 20 patients were assigned to the severe group and 37 patients were assigned to the non-severe group. Eleven patients in the severe group had a fatal outcome. In the severe and non-severe groups, HLA-A*02 and HLA-DQB1*03 were observed as the most frequent HLA alleles in HLA-A and HLA-DQB1 loci. For the other loci (HLA-DRB1, HLA-B, HLA-Cw), while HLA-DR1*04, HLA-B*35, and HLA-Cw*04 had the highest frequencies in their own loci in nonsevere cases, HLA-DR1*11, HLA-B*51, and HLA-Cw*12 had the highest frequencies in the severe group ( Table 2 ). The greater frequency of HLA-A*23 in severe cases was the only statistically significant difference between the two groups.
Discussion
An effective host immune response plays an important role in the response to infection. Genetic factors affect the functions of immune cells and finally the outcome of the infection. The association of HLA molecules with infections allows investigations to define the alleles affecting the susceptibility to infection or protection from infection in different ethnic groups, and to determine the genetic predisposition to specific infectious diseases, defining the population at risk.
1,2 Genetic studies may also provide the molecular basis for vaccine development studies. The mechanism of action of HLA genes on the immune response against viral particles and the production of neutralization antibodies provide an insight into the presentation of safe and efficient new viral vaccines. Several studies have sought to determine the association between bacterial, parasitic, and viral infectious diseases and HLA molecules. For instance, a relationship was demonstrated between the HLA-DR2 molecule and susceptibility to pulmonary tuberculosis. 15 The frequency of the HLA-DRB1 allele was found to be significantly higher in lepromatous leprosy patients than in tuberculoid leprosy patients. 16 In endemic regions, a protective role of the HLA molecules against malaria by control of the immune response has been well established. Investigations suggest that the relationship between HLA-B53 alleles and protection from severe malaria results from restriction of cytotoxic T lymphocytes during the liver stage of the parasite. 17, 18 The risk of kala-azar has been found to be higher in those persons positive for the HLA-A26 allele. 19 In viral infections, the HLA-restricted cytotoxic T-lymphocyte (CTL) response plays a major role in the host immune response against the viruses.
1 In particular, class I HLA molecules are very important for the lysis of infected cells by CTLs. An association between the HLA molecules and susceptibility or resistance to various viral infections has been found in several infections. 1, 2 There are numerous studies reporting the effect of the HLA molecules on the course of viral infections including HIV infection, dengue hemorrhagic fever, hantavirus infection, hepatitis B, hepatitis C, and Epstein-Barr virus infection. 20-25 However we could not find any study investigating the relationship between CCHF and HLA molecules. Several studies on hantavirus, which belongs to the same family (Bunyaviridae) as CCHF virus, have shown that the outcome of hemorrhagic fever with renal syndrome (HFRS) is determined by an interaction between the virus, immunological factors, and human genetics. A relationship between HLA alleles and the clinical course of the disease was established. 26, 27 Different associations of HLA molecules with different virus types have also been determined. The frequency of HLA-B*35 was found to be significantly higher in Dobrova virusinfected patients, while HLA-DRB1*13 was found to be significantly higher in Puumala virus infections. These HLA alleles were also found to be significantly higher in the severe form of the disease. However, HLA-B*07 allele was found to be more frequent in patients with mild disease and associated with a protective role against severe HFRS caused by Puumala virus. 25 The CCHF virus causes a delay in the adaptive immune response, which is critical for clearance of the virus. [28] [29] [30] The Table 2 The frequencies of HLA-A, HLA-B, HLA-Cw, HLA-DQB1, and HLA-DRB1 alleles in non-severe and severe cases HLA alleles Non-severe group, n (%) Severe group, n (%) p-Value adaptive immune response in humans involves the HLA system, which takes place in the presentation of pathogen-derived peptides to the T-cells and subsequently initiation of the adaptive immune response. 25 The severity of CCHF infection varies between patients. Some predictors of mortality have been defined in several clinical investigations. 14, [31] [32] [33] [34] These predictors are based on laboratory and clinical data. However there is no publication identifying the genetic predisposition toward the clinical course of the infection. In this study, the HLA-A*02 allele was more frequent in the patient group than in the healthy controls. Therefore, HLA-A*02 might be associated with susceptibility to the disease. On the other hand, HLA-B*27 might have a protective role in CCHF, since the frequency of HLA-B*27 was significantly lower in patients than in controls. A significant correlation between HLA-A*23 and severe CCHF cases was also detected, indicating that HLA-A*23 might be a genetic risk factor for progression to severe CCHF.
In conclusion, this study indicates that while some HLA alleles could constitute a risk factor for severe CCHF infection, others could have a protective role against the severe form of the disease. Of importance, this study presents the impact of genetic factors on the clinical course of the disease and will encourage further genetic studies in endemic populations. However, there are some limitations to this study. The number of patients was limited and only some HLA regions were investigated as genetic markers.
